Oslo, 29 August 2013 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has filed several patent applications within the area of vaccines. These applications will give PCI Biotech the opportunity to obtain further patent protection for the use of the PCI technology in vaccination, supplementing the already granted and pending patents within this area. PCI has the potential to enhance both prophylactic and therapeutic vaccines against a variety of diseases, such as cancer and infectious diseases.
The term of any granted patents resulting from this application would last until August 2033.
About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed treatment system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting the photosensitiser Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When the diseased cells are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.
PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.
The PCI technology is also a versatile and innovative vaccination platform, which may specifically increase the cytotoxic T-cell response of vaccines. This is particularly important in therapeutic vaccination, when the immune system needs to recognize and destroy diseased cells (e.g. virus infected cells and cancer).
PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021